Literature DB >> 25223582

Pulmonary venous hypertension and mechanical strain stimulate monocyte chemoattractant protein-1 release and structural remodelling of the lung in human and rodent chronic heart failure models.

John E S Park1, Alexander R Lyon2, Dongmin Shao3, Lauren R Hector1, Hua Xu4, Peter O'Gara5, Liao Pinhu1, Rachel C Chambers6, S John Wort7, Mark J D Griffiths7.   

Abstract

INTRODUCTION: The burden of chronic heart failure (HF) is rising owing to an increased survivorship after myocardial infarction (MI). Pulmonary structural remodelling in patients with HF may protect against oedema while causing dyspnoea, the predominant symptom associated with HF. The cellular and molecular mechanisms underlying these processes in HF are poorly understood. We hypothesised that pulmonary venous hypertension (PVH) following MI provides a mechanical stimulus for structural remodelling of the lung via monocyte chemoattractant protein-1 (MCP-1).
METHODS: Human lung microvascular endothelial cells (HLMVEC) and Ea.Hy 926 cells exposed to cyclic mechanical strain (CMS) in vitro were analysed for MCP-1 expression and activation of signalling intermediates. HF was induced in Sprague-Dawley rats 16 weeks after MI; a cohort was rescued with AAV9.SERCA2a gene therapy to reduce PVH.
RESULTS: HLMVEC and Ea.Hy 926 cells exposed to CMS upregulated MCP-1 gene expression and protein release in an extracellular-signal-regulated kinase (ERK) 1/2 dependent manner. Supernatants from these experiments stimulated fibroblast (human fetal lung fibroblast -1) and pulmonary artery smooth muscle cell proliferation and differentiation. Total lung collagen, a marker of structural remodelling, and MCP-1 gene expression were increased in the lungs of rats with post-MI HF. SERCA2a gene therapy that attenuated PVH after MI was associated with lower levels of lung collagen and MCP-1 gene expression in the lung.
CONCLUSIONS: Mechanical strain associated with PVH may stimulate pulmonary structural remodelling through ERK 1/2 dependent induction of MCP-1. These findings provide insights into the pathophysiology of lung remodelling in HF and highlight novel, potential therapeutic targets. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Pulmonary oedema; Systemic disease and lungs

Mesh:

Substances:

Year:  2014        PMID: 25223582     DOI: 10.1136/thoraxjnl-2013-204190

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  4 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Impact of reduced forced expiratory volume on cardiac prognosis in patients with chronic heart failure.

Authors:  Yuki Honda; Tetsu Watanabe; Yoichiro Otaki; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Yoko Shibata; Isao Kubota
Journal:  Heart Vessels       Date:  2018-03-19       Impact factor: 2.037

3.  Uterine overdistention induces preterm labor mediated by inflammation: observations in pregnant women and nonhuman primates.

Authors:  Kristina M Adams Waldorf; Natasha Singh; Aarthi R Mohan; Roger C Young; Lisa Ngo; Ananya Das; Jesse Tsai; Aasthaa Bansal; Louis Paolella; Bronwen R Herbert; Suren R Sooranna; G Michael Gough; Cliff Astley; Keith Vogel; Audrey E Baldessari; Theodor K Bammler; James MacDonald; Michael G Gravett; Lakshmi Rajagopal; Mark R Johnson
Journal:  Am J Obstet Gynecol       Date:  2015-08-15       Impact factor: 8.661

4.  Natural plant products in treatment of pulmonary arterial hypertension.

Authors:  Lili Xiang; Ying Li; Xu Deng; Djuro Kosanovic; Ralph Theo Schermuly; Xiaohui Li
Journal:  Pulm Circ       Date:  2018-06-05       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.